Top NYC, NY Biotech Companies With Best Stability & Growth (194)
Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, Click delivers accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Click’s treatments are defined by a commitment to applying technical and scientific rigor and patient-centric design to the development process. This...
Click Therapeutics's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Fresh capital arrived via a $50M April 2026 investment from Boehringer Ingelheim alongside an earlier Series C led by Dassault Systèmes/Medidata, extending resources for commercialization. The concurrent transfer of CT‑155 commercialization/marketing rights signals committed funding tied to revenue‑bearing activities.
Strategic Partnerships: Long‑running collaborations deepened with Boehringer Ingelheim (commercialization rights for CT‑155) and Otsuka (Rejoyn), while Dassault Systèmes/Medidata broadened a technology partnership to support scale‑up. A January 2026 partnership with Ultrahuman expands reach beyond traditional PDT channels.
Product Line Growth: Recent FDA authorizations for CT‑132 (episodic migraine) and Rejoyn (MDD) broaden the platform and advance the company toward launches. These milestones are highlighted as bolstering credibility for future products.
Formation Bio is a tech-driven pharma company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes all aspects of drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data capture. Formation Bio acquires clinical-stage drugs from pharma and biotech and develops them faster and more efficiently, unlocking greater...
Formation Bio's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Capital raised is described as substantial, with a $372M Series D in June 2024 led by a16z and participation from Sanofi, explicitly earmarked to grow the pipeline and AI platform. References to $600M+ in total funding and ongoing hiring point to a reinforced capital base supporting expansion.
Strategic Partnerships: Collaborations with Sanofi and OpenAI are presented as first-in-class efforts to apply AI across drug development, signaling external validation and increased resourcing. A 2025 Sanofi licensing deal worth up to €545M further indicates the capability to progress and transact assets with blue‑chip partners.
Product Line Growth: Pipeline activity is shown to be broadening via in‑licensing (e.g., a CNS‑penetrant TYK2 inhibitor in Dec 2025) and movement into the clinic, including first‑in‑human dosing on June 9, 2026. Together, these moves suggest more programs are entering and advancing through clinical stages.
We bring together one of the world’s largest libraries of multimodal clinical and molecular data with a robust suite of AI tools to help physicians personalize care in real time, connect patients with therapies and clinical trials, and enable partners to accelerate discovery and development of new treatments. With ~8 million de-identified research records and 350+ petabytes of data, Tempus partners...
Tempus AI's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is reported at about $1.27B for 2025 (~80–83% YoY), with Q4 2025 at $367.2M (+83% YoY) and Q1 2026 at $348.1M (+36% YoY); full‑year 2026 is guided to $1.59–$1.60B (~25% growth). Segment data show Diagnostics up 34.7% and Data & Applications up 40.5% YoY in Q1 2026.
Strategic Partnerships: Record total contract value exceeding $1.1B and multi‑year collaborations with AstraZeneca, Merck, Gilead, and Bristol Myers Squibb are highlighted. These arrangements support growth in data/software lines and add forward revenue visibility.
Product Line Growth: MRD testing reached ~6,500 in Q1 2026 (up ~500% YoY), and acquisitions of Ambry Genetics, Paige.AI, and Deep 6 AI broaden testing and AI capabilities. Management points to horizontal integration and cross‑selling (e.g., with Ambry) as contributors to expected growth.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Total revenue grew 23% year over year to $255.9M in 2025, with software up 10.6% and drug discovery more than doubling to $56.4M. Guidance for 2026 points to 10–15% software ACV growth, and Q1 2026 ACV rose 12% year over year.
Strategic Partnerships: Royalty‑eligible collaborative programs increased to 16 by year‑end 2025, with multiple partner milestones (e.g., Takeda’s TYK2 from Nimbus, Structure Therapeutics updates) and integrations like Lilly’s TuneLab in LiveDesign signaling ecosystem momentum. These relationships can generate milestones and potential royalties that support future growth.
Investor Backing & Capital Strength: Cash and marketable securities were about $402M at year‑end 2025 (approximately $406M at Q1 2026), and operating expenses are guided below 2025 levels for 2026. This liquidity and cost discipline provide runway to advance the hosted transition and the discovery portfolio.
At Inato, we’re on a mission to accelerate the pace of medical innovation by bringing clinical research to each and every patient, regardless of who they are and where they live. Our platform, made to connect community-based research centers to trials across the globe, aims to create greater visibility, access, and engagement across a more diverse population of doctors and...
Inato's Top Stability & Growth Strengths
Innovation-Driven Growth: AI site selection and AI patient pre-screening launched in 2025–2026 are described as streamlining screening and improving enrollment efficiency. These releases signal a deepening product footprint aligned to faster activation and more representative enrollment.
Strategic Partnerships: A 2025 data partnership with RealTime eClinical Solutions and highlighted work with major pharma logos are presented as ecosystem validation and traction. These collaborations integrate site performance data and extend marketplace reach.
Market Expansion: The network is portrayed as growing from about 5,500 to 6,000+ research sites across 50+ countries into 2026. Sponsor materials and industry posts indicate steady expansion of marketplace breadth.
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for...
Pfizer's Top Stability & Growth Strengths
Product Line Growth: Launched and acquired products are scaling, with oncology assets from the Seagen deal and brands such as Padcev, oncology biosimilars, Nurtec, Lorbrena, Abrysvo, Eliquis, and the Vyndaqel family cited as key contributors. Early‑2026 updates describe a meaningful uptick from these newer and in‑line medicines.
Innovation-Driven Growth: Management highlights a robust late‑stage pipeline with numerous pivotal study starts planned in 2026 and catalysts across oncology, vaccines, and metabolic disease. Programs such as an ADC (sigvotatug vedotin) and a GLP‑1 RA (berobenatide) are positioned to convert into future approvals and launches.
Diversified Revenue Streams: Growth beneath the surface is coming from multiple non‑COVID franchises rather than a single product, spanning oncology (including Seagen’s ADCs), vaccines, neurology, and cardiovascular. This breadth is helping to offset normalization in COVID‑related sales.
Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group.
Flatiron Health's Top Stability & Growth Strengths
Product Line Growth: Multiple 2026 launches and updates, including Flatiron Telescope, AI‑extracted real‑world progression, a new AI data‑quality framework, and harmonized multinational datasets, signal an expanding offering. A strong 2026 scientific presence (e.g., ASCO/ISPOR) showcases next‑generation capabilities aligned to growing use cases.
Market Expansion: International build‑out is evident in first AI‑powered prostate cancer datasets for the UK and Germany and new collaborations across the UK and Europe. Company materials also highlight a markedly larger multinational network spanning the UK, Germany, and Japan.
Strategic Partnerships: Collaborations with Unicancer for regulatory‑grade evidence and point‑of‑care integrations with Abbott and Quest indicate deepening enterprise engagement. Participation in ecosystem programs and multi‑year collaborations suggests a partner‑led growth approach.
PPD is now part of Thermo Fisher Scientific, the world leader in serving science. Together, Thermo Fisher and PPD are creating a unique opportunity to advance their shared pursuit to enable customers to make the world healthier by accelerating the development of new medicines. We now offer a comprehensive suite of world-class services across the clinical development spectrum – from...
A part of the over US$180 billion Tata Group, Tata Chemicals Limited, is a global company with interests in businesses that focus on Basic Chemistry Products and Specialty Chemistry Products. The story of the company is about harnessing the fruits of science for goals that go beyond business. The company’s Basic Chemistry product range provides key ingredients to some of...
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis...
Catalent Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health...
Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid’s broad test portfolio spans respiratory infections, blood virology, women’s and sexual health, TB and emerging...
Cepheid's Top Stability & Growth Strengths
Strong Market Position & Advantage: Evidence portrays Cepheid as a leader in near‑patient/sample‑to‑answer molecular diagnostics with a very large GeneXpert installed base and broad global reach. Multiple updates cite WHO‑endorsed TB assays and tens of thousands of instruments (exceeding 60,000 by 2024) underpinning recurring cartridge demand.
Innovation-Driven Growth: Recent regulatory wins (e.g., FDA clearance of the Xpert GI Panel and first‑in‑class POC HCV RNA authorization) and ongoing menu expansion signal sustained product innovation. Commentary highlights rapid test development and deployment across infectious diseases, helping drive non‑respiratory growth.
Strategic Partnerships: Collaborations with Oxford Nanopore, the Fleming Initiative, Oxford University, and CDC designations for rapid diagnostic advancement indicate strong ecosystem ties. These alliances aim to broaden use cases and strengthen platform adoption across settings.
Koneksa is a leading patient-centric digital biomarker company for the pharmaceutical and biotechnology industries that develops end-to-end solutions for remotely collected clinical data. Koneksa supports agile decision-making in drug development and market strategy. By delivering integrated solutions for efficient trial designs that produce more meaningful data, Koneksa aims to revolutionize effect detection in clinical research.
Headquartered in Brooklyn, New York, Cresilon, Inc. is a privately-held medical device company focused on hemostatic technologies that improve wound care and advance the standard of medical treatments. For more information, visit Cresilon.com. We are always looking for dynamic people to join our team as we dive into a range of challenges at the forefront of science and technology—to learn...
Lupin is a global pharmaceutical company offering Branded and Generic Formulations, Biosimilars and Active Pharmaceutical Ingredients (APIs). Founded over 50 years ago, Lupin today is a significant player in the US, India and Japan and additionally in other counties within APAC, EMEA and LATAM. It holds a global leadership position in Anti-TB and Cephalosporin segments. Today Lupin is focused on...
Together with our colleagues, customers and stakeholders, we impact life and health with science. Before researchers can make scientific breakthroughs, they must have access to state-of-the-art tools, services and expertise to perform experiments and engineer new products. That’s where we come in. We offer one of the broadest portfolios in the industry for scientists, best-in-class products for pharmaceutical development and...
Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Our mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. We focus on the discovery of RNA therapeutics. Over 30 million people in the US suffer from genetic diseases or cancer that...
Neogene Therapeutics is a global, clinical-stage biotechnology company pioneering the discovery, development, and manufacturing of next-generation engineered T cell receptor (TCR) therapies targeting a broad spectrum of solid cancers. With offices in Santa Monica, CA and Amsterdam, the Netherlands, Neogene is aiming to change the paradigm of treatment for solid cancers. Neogene is a member of the AstraZeneca Group
Kallyope is a platform biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis. The company integrates cutting-edge technologies in sequencing, computational biology, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that will lead to transformational therapeutics that improve human health. The company’s founders are Charles Zuker, Ph.D., Lasker Award...
Volastra Therapeutics, Inc. is a clinical stage oncology biotechnology company based in New York City. Founded by Lewis Cantley, Samuel Bakhoum and Olivier Elemento, Volastra is focused on developing therapeutics that exploit chromosomal instability (CIN) as a unique vulnerability in cancer. The company has grown since its founding in 2019 and now supports ongoing discovery efforts as well as a...
